Form 4 for EW Edwards Lifesciences
Accepted 2022-05-05 00:00:00 ET · period of report 2022-05-03 · accession 0001225208-22-006581 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-05 | 2022-05-04 | EW | Chopra Daveen | CVP, Surgical Structural Heart | F - Tax | $105.93 | -279 | 18.8K | -1% | -$29.6K |
| D | 2022-05-05 | 2022-05-03 | EW | Chopra Daveen | CVP, Surgical Structural Heart | A - Grant | $0.00 | +3,250 | 19.1K | +21% | $0 |
| DM | 2022-05-05 | 2022-05-03 | EW | Chopra Daveen | CVP, Surgical Structural Heart | A - Grant | $0.00 | +30.5K | 26.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-04 | F | D | 279 | $105.93 | 18,798 | D | — | — | |
| 2 | Common | Common Stock | 2022-05-03 | A | A | 3,250 | $0.00 | 19,077 | D | — | — | (F1) These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
| 3 | Derivative | Performance Rights | 2022-05-03 | A | A | 4,075 | $0.00 | 4,075 | D | — · 2025-05-03 to — | 4,075 Common Stock | (F3) Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. |
| 4 | Derivative | Employee Stock Option (Right to Acquire) | 2022-05-03 | A | A | 26,400 | $0.00 | 26,400 | D | $105.93 · 2023-05-03 to 2029-05-02 | 26,400 Common Stock | (F2) These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |